Neuphoria CEO Spyros Papapetropoulos Receives 34,559 Options

Rhea-AI Filing Summary

Neuphoria Therapeutics insider filing: Spyros Papapetropoulos, President, CEO and director of Neuphoria Therapeutics (NEUP), reported an option grant on 08/27/2025 for 34,559 employee stock options with an exercise price of $8.27 per share. The options vest monthly over four years beginning August 1, 2025, at a rate of 2.0833% of the shares on the last day of each month, and expire on 08/27/2035. After the grant, the reporting person beneficially owns 74,088 shares of common stock directly. The Form 4 was signed on 09/01/2025.

Positive

• Grant aligns executive incentives via a multi‑year, service‑based vesting schedule.
• Clear disclosure of transaction date, exercise price ($8.27), vesting schedule and post‑transaction ownership (74,088 shares).

Negative

• Potential dilution from 34,559 options, magnitude unknown without total share count.
• No information provided on total outstanding shares or previous option grants to assess incremental dilution or pay‑for‑performance metrics.

Insights

Securities Analyst

TL;DR Option grant of 34,559 shares at $8.27 vests monthly over four years; increases executive equity alignment.

The grant aligns senior management incentives with shareholder outcomes by providing a time‑based vesting schedule that requires continued service through monthly vesting events over four years. The $8.27 exercise price establishes the strike and the ten‑year term to 08/27/2035 offers long runway for potential upside. Immediate dilution from this grant is modest relative to total shares outstanding (not provided), but the filing increases the reporting person’s direct ownership to 74,088 shares, strengthening executive stake disclosure.

Corporate Governance Expert

TL;DR Standard service‑based option grant with customary vesting and long expiration is routine corporate governance practice.

The award uses typical terms: monthly vesting over four years and a ten‑year exercise window, which are common for executive compensation. The filing clearly discloses role, transaction date, vesting conditions and post‑transaction ownership. There is no indication in the Form 4 of accelerated vesting, transfers, or related‑party transactions. Material governance implications depend on aggregate executive compensation and dilution data not included in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Papapetropoulos Spyros

(Last) (First) (Middle)

100 SUMMIT DRIVE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuphoria Therapeutics Inc. [ NEUP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right-to- Buy)	$8.27	08/27/2025		A		34,559		(1)	08/27/2035	Common Stock	34,559	$8.27	74,088	D

Explanation of Responses:

1. Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested.

	/s/ Spyros Papapetropoulos	09/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NEUP insider Spyros Papapetropoulos report on Form 4?

He reported an option grant of 34,559 employee stock options on 08/27/2025 with an exercise price of $8.27 and a ten‑year term to 08/27/2035.

How do the options vest for the NEUP grant?

The options vest monthly over four years beginning August 1, 2025 at a rate of 2.0833% of the shares on the last day of each month.

How many NEUP shares does the reporting person own after the transaction?

The Form 4 shows the reporting person beneficially owns 74,088 shares of common stock following the reported transaction.

When was the Form 4 signed and filed?

The Form 4 was signed by Spyros Papapetropoulos on 09/01/2025 and reports a transaction date of 08/27/2025.

What is the expiration date of the granted options?

The options expire on 08/27/2035, giving a ten‑year exercise window from the grant date.